Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)
An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
Sponsor: Bioverativ Therapeutics Inc.
This PHASE3 trial investigates Severe Hemophilia B and is currently completed. Bioverativ Therapeutics Inc. leads this study, which shows 12 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bioverativ Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Atlanta, United States , Aurora, United States , Bangalore, India , Basingstoke, United Kingdom , Beijing, China , Bonn, Germany , Brussels, Belgium , Cambridge, United Kingdom , Campinas, Brazil and 37 more locations